We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Age-Related Macular Degeneration (AMD) - Beta Study Telemedicine Assessment (AMD)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01083147
First Posted: March 9, 2010
Last Update Posted: September 23, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Notal Vision Ltd
  Purpose
The purpose of this study is to evaluate the compliance of the Foresee Home device in intermediate AMD patients.

Condition Intervention
Age-Related Macular Degeneration Device: FORESEE HOME

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Age-Related Macular Degeneration (AMD) - Beta Study Telemedicine Assessment

Resource links provided by NLM:


Further study details as provided by Notal Vision Ltd:

Primary Outcome Measures:
  • Subject compliance with Foresee HomeTM device [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Assessment of the Telemedicine infrastructure [ Time Frame: 6 months ]

Enrollment: 50
Study Start Date: October 2009
Study Completion Date: September 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Dry AMD
subjects diagnosed as intermediate AMD in at least one eye
Device: FORESEE HOME
Home Monitoring

Detailed Description:
This is a non-randomized cohort, multi-center study. The eligible subjects will be asked to use the FORESEE HOME device daily and the tests results will be automatically transmitted to the Data Monitor Center for analysis.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
intermediate AMD
Criteria

Inclusion Criteria:

  • Subjects who successfully completed participation in ForeseeHome-US2 study
  • Patients with ability to comprehend and sign the informed consent/authorization

Exclusion Criteria:

  • Subjects who failed to complete participation in ForeseeHome-US2 study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01083147


Locations
United States, New Jersey
Vitreos retina center
Tom's river, New Jersey, United States
Sponsors and Collaborators
Notal Vision Ltd
Investigators
Principal Investigator: Daniel Roth, MD Vitreos retina center - NJ
  More Information

Responsible Party: Osnat Ehrman/Clinical manager, Notal Vision
ClinicalTrials.gov Identifier: NCT01083147     History of Changes
Other Study ID Numbers: ForeseeHome-US3
First Submitted: March 7, 2010
First Posted: March 9, 2010
Last Update Posted: September 23, 2010
Last Verified: September 2010

Keywords provided by Notal Vision Ltd:
Intermediate AMD

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases